COMP <GO>
MGX vs CVM // EV/EBITDA & P/E VALUATION
Metagenomi Therapeutics Inc. (NASDAQ) VS. Cel-Sci Corporation (NYSE) • 15-METRIC TALLY: MGX 1
— CVM 2
■ METRIC PARITY
LAST: $0.83 (+1.03%) • MKT CAP: $31.4M
valuation
—
LAST: $1.50 (-6.25%) • MKT CAP: $26.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MGX VS. CVM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MGX | CVM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -51.80% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | CVM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 36.0 | -5.00 | CVM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $31.4M | $26.4M | $5.0M | MGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MGX REV | CVM REV | MGX GROSS % | CVM GROSS % | MGX FCF | CVM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $25.2M | $0 | — | — | -$89.5M | -$17.2M |
| FY 2024 | $52.3M | $0 | — | — | -$112.2M | -$18.9M |
| FY 2023 | $44.8M | $0 | — | — | -$91.4M | -$22.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MGX // BETA —
CVM // BETA —